RNA editing, as a precise and reversible gene modification technology that does not introduce DNA double-strand breaks, is emerging as an important branch of RNA-based therapeutics. Unlike conventional strategies such as mRNA vaccines, siRNA, or antisense oligonucleotides that primarily alter the expression level of gene products, RNA editing directly corrects single nucleotides on RNA molecules, enabling precise restoration or modification of protein function at the transcript level. With the rapid development of novel editing enzymes, delivery systems, and target design strategies, RNA editing is transitioning from basic research to clinical exploration, showing unique potential in treating rare genetic disorders, neurodegenerative diseases, and certain metabolic conditions.